Literature DB >> 23295856

Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease.

Laura Rué1, Graciela López-Soop, Ellen Gelpi, Marta Martínez-Vicente, Jordi Alberch, Esther Pérez-Navarro.   

Abstract

Huntington's disease is characterized by the formation of protein aggregates, which can be degraded by macroautophagy. Here, we studied protein levels and intracellular distribution of p62 and NBR1, two macroautophagy cargo receptors, during disease progression. In R6/1 mice, p62 and NBR1 protein levels were decreased in all brain regions analyzed early in the disease, whereas at late stages they accumulated in the striatum and hippocampus, but not in the cortex. The accumulation of p62, but not NBR1, occurred in neuronal nuclei, where it co-localized with mutant huntingtin inclusions, both in R6/1 and Huntington's disease patients. Moreover, exportin-1 was selectively decreased in old R6/1 mice brain, and could worsen p62 nuclear accumulation. In conclusion, p62 interacts with mutant huntingtin and is retained in the nucleus along the progression of the disease, mostly in striatal and hippocampal neurons. Thus, cytoplasmic NBR1 might be important to maintain basal levels of selective macroautophagy in these neurons.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295856     DOI: 10.1016/j.nbd.2012.12.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  16 in total

1.  Dominant-negative function of the C-terminal fragments of NBR1 and SQSTM1 generated during enteroviral infection.

Authors:  J Shi; G Fung; P Piesik; J Zhang; H Luo
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

2.  Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.

Authors:  Jordi Creus-Muncunill; Laura Rué; Rafael Alcalá-Vida; Raquel Badillos-Rodríguez; Joan Romaní-Aumedes; Sonia Marco; Jordi Alberch; Isabel Perez-Otaño; Cristina Malagelada; Esther Pérez-Navarro
Journal:  Mol Neurobiol       Date:  2018-02-19       Impact factor: 5.590

Review 3.  SQSTM1/p62: A Potential Target for Neurodegenerative Disease.

Authors:  Shifan Ma; Insiya Y Attarwala; Xiang-Qun Xie
Journal:  ACS Chem Neurosci       Date:  2019-04-19       Impact factor: 4.418

Review 4.  Selective autophagy as a potential therapeutic target for neurodegenerative disorders.

Authors:  Aurora Scrivo; Mathieu Bourdenx; Olatz Pampliega; Ana Maria Cuervo
Journal:  Lancet Neurol       Date:  2018-09       Impact factor: 44.182

5.  Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

Authors:  Laura Rué; Mónica Bañez-Coronel; Jordi Creus-Muncunill; Albert Giralt; Rafael Alcalá-Vida; Gartze Mentxaka; Birgit Kagerbauer; M Teresa Zomeño-Abellán; Zeus Aranda; Veronica Venturi; Esther Pérez-Navarro; Xavier Estivill; Eulàlia Martí
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

Review 6.  Macroautophagy in CNS health and disease.

Authors:  Christopher J Griffey; Ai Yamamoto
Journal:  Nat Rev Neurosci       Date:  2022-05-03       Impact factor: 38.755

Review 7.  From autophagy to mitophagy: the roles of P62 in neurodegenerative diseases.

Authors:  Haiying Liu; Chunqiu Dai; Yunlong Fan; Baolin Guo; Keke Ren; Tangna Sun; Wenting Wang
Journal:  J Bioenerg Biomembr       Date:  2017-10-03       Impact factor: 2.945

8.  p62 provides dual cytoprotection against oxidative stress in the retinal pigment epithelium.

Authors:  Lei Wang; Marisol Cano; James T Handa
Journal:  Biochim Biophys Acta       Date:  2014-03-22

Review 9.  Macroautophagy and aging: The impact of cellular recycling on health and longevity.

Authors:  Jose L Nieto-Torres; Malene Hansen
Journal:  Mol Aspects Med       Date:  2021-09-07

10.  Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease.

Authors:  Ana Saavedra; Albert Giralt; Helena Arumí; Jordi Alberch; Esther Pérez-Navarro
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.